Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimers disease》.pdfVIP

Neurobiology of Disease 34 (2009) 525–534 Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www. elsevi /locate/ynbdi Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimers disease Shaila P. Handattu a,⁎, David W. Garber a,⁎, Candyce E. Monroe a, Thomas van Groen c, Inga Kadish c, Gaurav Nayyar a, Dongfeng Cao a, Mayakonda N. Palgunachari a, Ling Li a, G.M. Anantharamaiah a,b a Atherosclerosis Research Unit and Department of Medicine, University of Alabama at Birmingham Medical Center, Birmingham, AL-35294, USA b Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham Medical Center, Birmingham, AL-35294, USA c Department of Cell Biology, University of Alabama at Birmingham Medical Center, Birmingham, AL-35294, USA a r t i c l e i n f o a b s t r a c t Article history: Recent evidence indicates that inflammation may significantly contribute to the pathogenesis of Alzheimers Received 23 September 2008 disease (AD). Since the apo A-I mimetic peptide D-4F has been shown to inhibit atherosclerotic lesion Revised 11 February 2009 formation and regress already existing lesions (in the presence of pravastatin) and the peptide also Accepted 18 March 2009 decreases brain arteriole inflammation, we undertook a study to evaluate the efficacy of oral D-4F co- Available online 1 April 2009 administered with pravastatin on cognitive function and amyl